Ivonescimab plus chemo before chemoradiation for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests giving the immunotherapy drug ivonescimab with chemotherapy before standard chemoradiation in women with high-risk, locally advanced cervical cancer that has not spread to distant organs. The goal is to see if this combination can improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have cervical cancer confirmed by biopsy.
- Your cancer must be a type called squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
- Your cancer must be stage III or IVA and not removable by surgery.
- You cannot have had any prior cancer treatment like chemotherapy, radiation, or surgery for this cancer.
- You must have at least one tumor that can be measured on scans.
- Your tumor must have a PD-L1 CPS score of at least 1 (a test done on your biopsy sample).
- You must have good kidney, liver, and blood cell function as shown by lab tests.
- You cannot be pregnant and must use effective birth control during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
This trial tests a new immunotherapy drug (enlansibumab) given together with standard chemoradiation for locally advanced cervical cancer. It aims to see if adding this drug helps shrink tumors and improves outcomes.
This trial tests adding a new drug called Ivonescimab to standard chemotherapy (paclitaxel and cisplatin) given before a hysterectomy in women with cervical cancer stage IB2 or IIA1 (tumor size 2-4 cm). The goal is to see if this combination improves outcomes compared to chemo alone.
This trial tests combining standard chemoradiation with a PD-1 inhibitor (a drug that helps your immune system fight cancer) for advanced cervical cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatment alone.
This trial tests a new combination of chemotherapy and immunotherapy before standard chemoradiation for locally advanced cervical cancer. The goal is to see if adding immunotherapy first helps shrink the tumor and improve treatment outcomes.
This Phase 2 study tests whether adding immunotherapy (nivolumab and ipilimumab) to standard chemoradiation can improve treatment for cervical cancer. It may help by training the immune system to better target cancer cells while radiation and chemotherapy work in the body.
Hear when a new LOCALLY ADVANCED CERVICAL CANCERS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.